Bristol Myers Squibb and RayzeBio announce the expiration, on the evening of February 9, of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with the former's previously announced tender offer for the latter.

As a reminder, the offer is to acquire all outstanding shares of RayzeBio common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion.

The expiration of the HSR period removes one of the conditions to the completion of the transaction, which remains subject, among other things, to the contribution of the majority of RayzeBio shares to the tender offer. Unless extended, this period will expire on the evening of February 22.

Copyright (c) 2024 All rights reserved.